888-969-2592
Kalkine 0
countryflagCA

Cognition Therapeutics Inc

Healthcare US CGTX

0.6613USD
-0.0187(2.75%)

Last update at 2025-07-18T16:57:00Z

Day Range

0.670.71
LowHigh

52 Week Range

0.342.95
LowHigh

Fundamentals

  • Previous Close 0.68
  • Market Cap19.02M
  • Volume2017582
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-58.60900M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.96

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -21.39700M -11.71600M -7.83900M -4.84200M
Minority interest - - - -
Net income 0.76M -10.28500M -10.07200M -6.95300M
Selling general administrative 13.23M 10.03M 4.52M 3.45M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation 0.23M 0.09M 0.10M 0.08M
Ebit -43.55100M -28.59800M -17.40700M -17.83100M
Ebitda -21.13400M -13.38200M -5.97200M -3.49900M
Depreciation and amortization 22.42M 15.22M 11.44M 14.33M
Non operating income net other -0.03500M - - -
Operating income -43.55100M -28.59800M -17.40700M -17.83100M
Other operating expenses 21.33M 11.15M 6.55M 4.67M
Interest expense 0.03M 0.89M 1.75M 1.02M
Tax provision - - - -
Interest income - - - -
Net interest income -0.02800M -0.89300M -1.75100M -1.02400M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -22.15400M -1.43100M 2.23M 2.11M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 21.33M 11.15M 6.55M 4.67M
Cost of revenue - - - -
Total other income expense net 22.15M 16.88M 9.57M 12.99M
Discontinued operations - - - -
Net income from continuing ops -43.61400M -11.71600M -7.83900M -4.84200M
Net income applicable to common shares -21.39700M -16.24800M -12.07300M -8.76200M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 35.16M 50.42M 59.14M 7.12M 7.46M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.02M 2.41M 0.01M 0.02M 0.03M
Total liab 10.69M 10.18M 7.86M 75.30M 65.88M
Total stockholder equity 24.47M 40.25M 51.27M -68.18400M -58.42200M
Deferred long term liab - - - - -
Other current liab 4.60M 2.09M 3.70M 1.25M 0.00100M
Common stock 0.03M 0.03M 0.02M 0.00100M 0.00100M
Capital stock 0.03M 0.03M 0.02M 0.00100M 0.00100M
Retained earnings -141.18900M -115.40100M -94.00400M -68.22000M -58.23900M
Other liab - - - 3.83M 2.37M
Good will - - - - -
Other assets 0.00000M - - - -
Cash 29.92M 41.56M 54.72M 5.19M 2.89M
Cash and equivalents - - - - -
Total current liabilities 10.17M 7.79M 7.86M 3.25M 3.68M
Current deferred revenue 1.70M 1.70M - - 1.32M
Net debt -29.74800M -40.08400M -54.72100M 7.66M 4.01M
Short term debt 0.17M 0.78M - - 0.00400M
Short long term debt 0.54M 0.63M - - -
Short long term debt total 0.17M 1.48M - 12.85M 6.90M
Other stockholder equity 165.83M 155.82M 86.32M 0.22M 0.00100M
Property plant equipment - 0.23M 0.14M 0.21M 0.30M
Total current assets 34.22M 47.65M 58.99M 6.91M 7.16M
Long term investments - - - - -
Net tangible assets - 40.25M 51.27M -68.18400M -58.42200M
Short term investments - - - - -
Net receivables 1.28M 3.67M 2.27M 1.15M 4.12M
Long term debt - - - 12.85M 6.90M
Inventory - - 1.99M 0.54M 0.12M
Accounts payable 3.69M 3.22M 4.17M 2.00M 2.36M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.19500M -0.19900M -0.19800M -0.18700M -0.18500M
Additional paid in capital - - - - -
Common stock total equity - 0.03M - - -
Preferred stock total equity - - - - -
Retained earnings total equity - -115.40100M - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M 1.73M - - -
Deferred long term asset charges - - - - -
Non current assets total 0.94M 2.78M 0.14M 0.21M 0.30M
Capital lease obligations 0.69M 0.84M - 0.00000M 0.00400M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.17100M -0.02700M -0.01000M -0.14400M
Change to liabilities -0.74900M 2.17M -0.36400M 0.86M
Total cashflows from investing activities -0.17100M -0.02700M -0.01000M -0.14400M
Net borrowings -1.39600M -0.26800M 5.81M 2.83M
Total cash from financing activities 5.55M 53.20M 5.76M 2.79M
Change to operating activities - 0.56M 2.53M 0.78M
Net income -21.39700M -11.71600M -7.83900M -4.84200M
Change in cash -13.15900M 49.53M 2.30M -0.50800M
Begin period cash flow 54.72M 5.19M 2.89M 3.40M
End period cash flow 41.56M 54.72M 5.19M 2.89M
Total cash from operating activities -18.53300M -3.63100M -3.43300M -3.09800M
Issuance of capital stock 5.32M 44.22M - -
Depreciation 0.23M 0.09M 0.10M 0.08M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - 0.12M 0.90M -1.07500M
Sale purchase of stock 6.94M - - -
Other cashflows from financing activities 1.62M 9.25M 5.77M 2.84M
Change to netincome 3.57M 4.77M 0.41M 0.60M
Capital expenditures 0.17M 0.03M 0.01000M 0.14M
Change receivables 0.47M - - -
Cash flows other operating -0.50900M - - -
Exchange rate changes - - - -
Cash and cash equivalents changes -13.15800M - - -
Change in working capital -0.94300M 2.84M 3.07M 0.57M
Stock based compensation 3.57M 5.18M 0.47M 0.36M
Other non cash items - 0.38M 0.84M 0.49M
Free cash flow -18.70400M -3.65800M -3.44300M -3.24200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CGTX
Cognition Therapeutics Inc		 -0.0187 2.75% 0.66 - - - 1.22 -0.4433
NVO
Novo Nordisk A/S		 -1.07 1.64% 64.22 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 65.44 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.81 0.39% 461.46 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -6.63 1.21% 543.37 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Cognition Therapeutics Inc

2500 Westchester Ave., Purchase, NY, United States, 10577

Key Executives

Name Title Year Born
Ms. Lisa Ricciardi CEO, Pres & Director 1960
Dr. Anthony O. Caggiano M.D., Ph.D. Chief Medical Officer and Head of R&D NA
Mr. Andrew J. Einhorn CPA Interim Chief Financial Officer 1960
Ms. Lisa Ricciardi CEO, President & Director 1960
Mr. John Brendan Doyle Chief Financial Officer 1977
Dr. Steven A. Weissman Ph.D. VP & Head of CMC NA
Dr. Anthony O. Caggiano M.D., Ph.D. Chief Medical Officer and Head of R&D 1970
Ms. Anita Cornet Head of Quality NA
Mr. Bobby Horn Corporate Controller NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.